全文获取类型
收费全文 | 345篇 |
免费 | 24篇 |
国内免费 | 1篇 |
专业分类
儿科学 | 7篇 |
妇产科学 | 16篇 |
基础医学 | 40篇 |
口腔科学 | 4篇 |
临床医学 | 27篇 |
内科学 | 62篇 |
皮肤病学 | 7篇 |
神经病学 | 54篇 |
特种医学 | 15篇 |
外科学 | 25篇 |
综合类 | 4篇 |
一般理论 | 2篇 |
预防医学 | 23篇 |
眼科学 | 4篇 |
药学 | 37篇 |
中国医学 | 2篇 |
肿瘤学 | 41篇 |
出版年
2023年 | 5篇 |
2022年 | 9篇 |
2021年 | 16篇 |
2020年 | 9篇 |
2019年 | 10篇 |
2018年 | 7篇 |
2017年 | 5篇 |
2016年 | 5篇 |
2015年 | 3篇 |
2014年 | 11篇 |
2013年 | 7篇 |
2012年 | 16篇 |
2011年 | 28篇 |
2010年 | 8篇 |
2009年 | 9篇 |
2008年 | 33篇 |
2007年 | 17篇 |
2006年 | 22篇 |
2005年 | 26篇 |
2004年 | 17篇 |
2003年 | 10篇 |
2002年 | 22篇 |
2001年 | 10篇 |
2000年 | 11篇 |
1999年 | 8篇 |
1998年 | 6篇 |
1997年 | 3篇 |
1996年 | 6篇 |
1995年 | 1篇 |
1994年 | 1篇 |
1993年 | 3篇 |
1992年 | 5篇 |
1991年 | 3篇 |
1990年 | 2篇 |
1989年 | 4篇 |
1988年 | 4篇 |
1987年 | 1篇 |
1985年 | 1篇 |
1982年 | 1篇 |
1975年 | 1篇 |
1974年 | 1篇 |
1973年 | 2篇 |
1971年 | 1篇 |
排序方式: 共有370条查询结果,搜索用时 15 毫秒
1.
Voltage-dependent priming of rat vanilloid receptor: effects of agonist and protein kinase C activation 总被引:4,自引:2,他引:2
The responses of vanilloid receptor (VR) channels to changing membrane potential were studied in Xenopus oocytes and rat dorsal root ganglion (DRG) neurons. In oocytes, capsaicin-evoked VR currents increased instantaneously upon a step depolarization and thereafter rose biexponentially with time constants of ≈20 and 1000 ms. Similarly, upon repolarization the current abruptly decreased, followed by a biexponential decay with time constants of ≈4 and 200 ms. Qualitatively similar effects were observed in single channel recordings of native VR channels from DRG neurons and with endogenous VR activators, including heat (43 °C), H+ , anandamide and protein kinase C (PKC). The magnitude of the time-dependent current rise increased with membrane depolarization. This effect was accompanied by an increase in the relative proportion of the fast kinetic component, A 1 . In contrast, the time constants of the activation and deactivation processes were not strongly voltage dependent. Increasing the agonist concentration both reduced the magnitude of the current rise and increased its overall rate, without significantly altering the deactivation rate. In contrast, PKC both speeded the current rise and slowed its decay. These results suggest that voltage interacts with agonists in a synergistic manner to augment VR current and this mechanism will be enhanced under conditions of inflammation when VRs are likely to be phosphorylated. 相似文献
2.
Analysis of the butyrylcholinesterase gene and nearby chromosome 3 markers in Alzheimer disease 总被引:3,自引:0,他引:3
Brindle N; Song Y; Rogaeva E; Premkumar S; Levesque G; Yu G; Ikeda M; Nishimura M; Paterson A; Sorbi S; Duara R; Farrer L; St George-Hyslop P 《Human molecular genetics》1998,7(5):933-935
The K-variant of butyrylcholinesterase (BCHE-K) recently has been reported
to be associated with Alzheimer disease (AD) in carriers of the epsilon4
allele of the apolipoprotein E (APOE) gene. We have re- examined the
frequency of the BCHE-K allele in a large data set of both sporadic and
familial cases of AD disease, and we have also examined the segregation of
three genetic markers on chromosome 3 near BCHE . Our data neither support
an association of BCHE-K with sporadic or familial AD, nor do they suggest
the existence of another gene nearby on chromosome 3 as a common cause of
familial AD.
相似文献
3.
Projected Economic Burden of Periprosthetic Joint Infection of the Hip and Knee in the United States
Ajay Premkumar David A. Kolin Kevin X. Farley Jacob M. Wilson Alexander S. McLawhorn Michael B. Cross Peter K. Sculco 《The Journal of arthroplasty》2021,36(5):1484-1489.e3
BackgroundIn addition to the significant morbidity and mortality associated with periprosthetic joint infection (PJI), the cost of treating PJI is substantial. Prior high-quality national estimates of the economic burden of PJI utilize data up to 2009 to project PJI growth in the United States through 2020. Now in the year 2020, it is appropriate to evaluate these past projections and incorporate the latest available data to better understand the current scale and burden of PJI in the United States.MethodsThe Nationwide Inpatient Sample (2002-2017) was used to identify rates and associated inpatient costs for primary total knee arthroplasty (TKA) and total hip arthroplasty (THA) and PJI-related revision TKA and THA. Poisson regression was utilized to model past growth and project future rates and cost of PJI of the hip and knee.ResultsUsing the most recent data, the combined annual hospital costs related to PJI of the hip and knee were estimated to be $1.85 billion by 2030. This includes $753.4 million for THA PJI and $1.1 billion for TKA PJI, in that year. Increases in PJI costs are mainly attributable to increases in volume. Although the growth in incidence of primary THA and TKA has slowed in recent years, the incidence of PJI and the cost per case of PJI remained relatively constant from 2002 to 2017.DiscussionUnderstanding the current and potential future financial burden of PJI for surgeons, patients, and healthcare systems is essential. There is an urgent need for efficacious preventive strategies in reducing rates of PJI after THA and TKA. 相似文献
4.
Wilk JB Premkumar S Nicolaou M Myers RH Maher NE Harmon MD Farrer LA DeStefano AL Cupples LA Couropmitree NN 《Genetic epidemiology》1999,17(Z1):S761-S766
Linkage analysis was performed on the GAW11 Problem 2 data set using stratification to explore the effects of the environmental risk factors and the differences between mild and severe phenotypes. Analysis of the four study populations stratified by the two risk factors identified regions on chromosomes 3 and 5 with significant evidence for linkage. Other loci were sought by removing families consistent with linkage to the chromosome 3 locus. Our studies identified a locus on chromosome 3 (markers 43-46) associated with the mild phenotype in the presence of risk factor 1 and with the severe phenotype independent of risk factor 1. This suggests that distinct allelic variants at the chromosome 3 locus may cause different forms of disease. The locus identified on chromosome 5 (markers 36-39) was linked to the severe phenotype, but exposure to factor 1 or 2 may have a protective effect. The regions on chromosomes 3 and 5 appeared to have independent roles in disease etiology. Evidence for two loci on chromosome 1 linked to the mild form was found. The methods successfully identified linkages and interaction consistent with the generating model. 相似文献
5.
Nicolaou M Premkumar S DeStefano AL Farrer LA Cupples LA 《Genetic epidemiology》1999,17(Z1):S679-S684
Knowing the answers, we used the GAW11 data set to compare the power and efficiency of discordant versus concordant affected sib pairs for qualitative traits at different levels of penetrance. Samples of 200 concordant sib pairs outperformed discordant sib pairs for low penetrance (40%) and 70% penetrance models while at 90% penetrance they performed equally well. Increasing the sample size of discordant sib pairs to twice that of concordant pairs was not enough to reach the power of concordant sib pairs at the 40% and 70% penetrance models. For low penetrance using a combination of concordant and discordant sib pairs resulted in higher power than using discordant sib pairs alone. At 90% penetrance, the power of concordant and discordant sib pairs was similar in the region close to the gene while concordant sib pairs performed better at locations further from the gene. 相似文献
6.
Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity 总被引:1,自引:0,他引:1
Bingham A Mamyrova G Rother KI Oral E Cochran E Premkumar A Kleiner D James-Newton L Targoff IN Pandey JP Carrick DM Sebring N O'Hanlon TP Ruiz-Hidalgo M Turner M Gordon LB Laborda J Bauer SR Blackshear PJ Imundo L Miller FW Rider LG;Childhood Myositis Heterogeneity Study Group 《Medicine》2008,87(2):70-86
We describe the clinical features of 28 patients with juvenile dermatomyositis (JDM) and 1 patient with adult-onset dermatomyositis (DM), all of whom developed lipodystrophy (LD) that could be categorized into 1 of 3 phenotypes, generalized, partial, or focal, based on the pattern of fat loss distribution. LD onset was often delayed, beginning a median of 4.6 years after diagnosis of DM. Calcinosis, muscle atrophy, joint contractures, and facial rash were DM disease features found to be associated with LD. Panniculitis was associated with focal lipoatrophy while the anti-p155 autoantibody, a newly described myositis-associated autoantibody, was more associated with generalized LD. Specific LD features such as acanthosis nigricans, hirsutism, fat redistribution, and steatosis/nonalcoholic steatohepatitis were frequent in patients with LD, in a gradient of frequency and severity among the 3 sub-phenotypes. Metabolic studies frequently revealed insulin resistance and hypertriglyceridemia in patients with generalized and partial LD. Regional fat loss from the thighs, with relative sparing of fat loss from the medial thighs, was more frequent in generalized than in partial LD and absent from DM patients without LD. Cytokine polymorphisms, the C3 nephritic factor, insulin receptor antibodies, and lamin mutations did not appear to play a pathogenic role in the development of LD in our patients. LD is an under-recognized sequela of JDM, and certain DM patients with a severe, prolonged clinical course and a high frequency of calcinosis appear to be at greater risk for the development of this complication. High-risk JDM patients should be screened for metabolic abnormalities, which are common in generalized and partial LD and result in much of the LD-associated morbidity. Further study is warranted to investigate the pathogenesis of acquired LD in patients with DM. 相似文献
7.
Mehtani Rohit Garg Shankey Kajal Kamal Soni Shiv Lal Premkumar Madhumita 《Metabolic brain disease》2022,37(5):1291-1307
Metabolic Brain Disease - Patients with liver disease often have alteration of neurological status which requires admission to an intensive care unit. Patients with acute liver failure (ALF),... 相似文献
8.
Arioglu E Duncan-Morin J Sebring N Rother KI Gottlieb N Lieberman J Herion D Kleiner DE Reynolds J Premkumar A Sumner AE Hoofnagle J Reitman ML Taylor SI 《Annals of internal medicine》2000,133(4):263-274
BACKGROUND: Troglitazone promotes adipocyte differentiation in vitro and increases insulin sensitivity in vivo. Therefore, troglitazone may have therapeutic benefit in lipoatrophic diabetes. OBJECTIVE: To determine whether troglitazone ameliorates hyperglycemia and hypertriglyceridemia or increases fat mass in lipoatrophic patients. DESIGN: Open-labeled prospective study. SETTING: United States and Canada. PATIENTS: 20 patients with various syndromes associated with lipoatrophy or lipodystrophy. INTERVENTION: 6 months of therapy with troglitazone, 200 to 600 mg/d. MEASUREMENTS: Levels of hemoglobin A1c triglycerides, free fatty acids, and insulin; respiratory quotient; percentage of body fat; liver volume; and regional fat mass. RESULTS: In the 13 patients with diabetes who completed 6 months of troglitazone therapy, hemoglobin A1c levels decreased by a mean of 2.8% (95% CI, 1.9% to 3.7%; P < 0.001). In all 19 study patients, fasting triglyceride levels decreased by 2.6 mmol/L (230 mg/dL) (CI, 0.7 to 4.5 mmol/L [62 to 398 mg/dL]; P = 0.019) and free fatty acid levels decreased by 325 micromol/L (CI, 135 to 515 micromol/L; P = 0.035). The respiratory quotient decreased by a mean of 0.12 (CI, 0.08 to 0.16; P < 0.001), suggesting that troglitazone promoted oxidation of fat. Body fat increased by a mean of 2.4 percentage points (CI, 1.3 to 4.5 percentage points; P = 0.044). Magnetic resonance imaging showed an increase in subcutaneous adipose tissue but not in visceral fat. In one patient, the serum alanine aminotransferase level increased eightfold during the 10th months of troglitazone treatment but normalized 3 months after discontinuation of treatment Liver biopsy revealed an eosinophilic infiltrate, suggesting hypersensitivity reaction as a cause of hepatotoxicity. CONCLUSION: Troglitazone therapy improved metabolic control and increased body fat in patients with lipoatrophic diabetes. The substantial benefits of troglitazone must be balanced against the risk for hepatotoxicity, which can occur relatively late in the treatment course. 相似文献
9.
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance 总被引:17,自引:0,他引:17 下载免费PDF全文
Gumireddy K Baker SJ Cosenza SC John P Kang AD Robell KA Reddy MV Reddy EP 《Proceedings of the National Academy of Sciences of the United States of America》2005,102(6):1992-1997
Imatinib, which is an inhibitor of the BCR-ABL tyrosine kinase, has been a remarkable success for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemias (CMLs). However, a significant proportion of patients chronically treated with imatinib develop resistance because of the acquisition of mutations in the kinase domain of BCR-ABL. Mutations occur at residues directly implicated in imatinib binding or, more commonly, at residues important for the ability of the kinase to adopt the specific closed (inactive) conformation to which imatinib binds. In our quest to develop new BCR-ABL inhibitors, we chose to target regions outside the ATP-binding site of this enzyme because these compounds offer the potential to be unaffected by mutations that make CML cells resistant to imatinib. Here we describe the activity of one compound, ON012380, that can specifically inhibit BCR-ABL and induce cell death of Ph+ CML cells at a concentration of <10 nM. Kinetic studies demonstrate that this compound is not ATP-competitive but is substrate-competitive and works synergistically with imatinib in wild-type BCR-ABL inhibition. More importantly, ON012380 was found to induce apoptosis of all of the known imatinib-resistant mutants at concentrations of <10 nM concentration in vitro and cause regression of leukemias induced by i.v. injection of 32Dcl3 cells expressing the imatinib-resistant BCR-ABL isoform T315I. Daily i.v. dosing for up to 3 weeks with a >100 mg/kg concentration of this agent is well tolerated in rodents, without any hematotoxicity. 相似文献
10.
The complement system is profoundly involved in the pathogenesis of acetylcholine receptor (AChR) antibody (Ab) related myasthenia gravis (MG) and its animal model experimental autoimmune myasthenia gravis (EAMG). The most characteristic finding of muscle pathology in both MG and EAMG is the abundance of IgG and complement deposits at the nerve–muscle junction (NMJ), suggesting that AChR-Ab induces muscle weakness by complement pathway activation and consequent membrane attack complex (MAC) formation. This assumption has been supported with EAMG resistance of complement factor C3 knockout (KO), C4 KO and C5 deficient mice and amelioration of EAMG symptoms following treatment with complement inhibitors such as cobra venom factor, soluble complement receptor 1, anti-C1q, anti-C5 and anti-C6 Abs. Moreover, the complement inhibitor decay accelerating factor (DAF) KO mice exhibit increased susceptibility to EAMG. These findings have brought forward improvisation of novel therapy methods based on inhibition of classical and common complement pathways in MG treatment. 相似文献